Identifying Epigenomic Mechanisms of Breast Cancer From Circulating Cell-free DNA

Paul Giresi, PhD
Chief Scientific Officer, Ravel Biotechnology

Register in advance for this webinar

Paul Giresi, PhD is the Chief Scientific Officer at Ravel Biotechnology and is leading efforts to commercialize the company’s diagnostic products for early disease detection. Giresi is also devising strategies to address regulatory and stakeholder requirements to bring Ravel tests to market. Giresi has over 20 years of experience developing epigenomic technologies and analytic tools for improving human health in both industry and academia. These technologies have been widely adopted across a variety of research efforts, including international consortia formed to investigate the epigenome (ENCODE). As an American Cancer Society fellow at Stanford University, he invented ATAC-seq, which has rapidly become the standard for measuring the epigenome. In 2013 Giresi co-founded Epinomics based on his ATAC-seq technology – Epinomics was later acquired by 10x Genomics in 2018. In his free time, Giresi enjoys spending time with family and friends.